[
  {
    "ts": null,
    "headline": "Solventum Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags",
    "summary": "Solventum ( NYSE:SOLV ) Second Quarter 2025 Results Key Financial Results Revenue: US$2.16b (up 3.8% from 2Q 2024). Net...",
    "url": "https://finnhub.io/api/news?id=fbb5815d2b049978dfb2f8299d43686ce19aa6223d9e6660d3b354b33297cef5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755174580,
      "headline": "Solventum Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags",
      "id": 136349971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Solventum ( NYSE:SOLV ) Second Quarter 2025 Results Key Financial Results Revenue: US$2.16b (up 3.8% from 2Q 2024). Net...",
      "url": "https://finnhub.io/api/news?id=fbb5815d2b049978dfb2f8299d43686ce19aa6223d9e6660d3b354b33297cef5"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Solventum’s Q2 Earnings Call",
    "summary": "Solventum delivered a positive Q2, with the market responding favorably to its earnings results. The company’s outperformance was fueled by momentum across its core business segments, notably MedSurg, where targeted commercial restructuring and a focused approach to high-growth categories paid off. CEO Bryan Hanson attributed progress to “existing and differentiated brands, recent new product launches, and commercial restructuring to specialize the sales channel in our growth driver areas.” The",
    "url": "https://finnhub.io/api/news?id=04cb0f3e94876b640b8db7b1dcd9dd4ee35acdf49d6b605e5849ce1a0590f1f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755149651,
      "headline": "5 Insightful Analyst Questions From Solventum’s Q2 Earnings Call",
      "id": 136345211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Solventum delivered a positive Q2, with the market responding favorably to its earnings results. The company’s outperformance was fueled by momentum across its core business segments, notably MedSurg, where targeted commercial restructuring and a focused approach to high-growth categories paid off. CEO Bryan Hanson attributed progress to “existing and differentiated brands, recent new product launches, and commercial restructuring to specialize the sales channel in our growth driver areas.” The",
      "url": "https://finnhub.io/api/news?id=04cb0f3e94876b640b8db7b1dcd9dd4ee35acdf49d6b605e5849ce1a0590f1f8"
    }
  },
  {
    "ts": null,
    "headline": "Solventum Announces Pricing of Secondary Offering of Common Stock",
    "summary": "Solventum Corporation (NYSE: SOLV) (the \"Company\" or \"Solventum\") today announced the pricing of the previously announced secondary offering (the \"Offering\") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the \"Selling Shareholder\"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any of the proceeds from the Offering. The Offering is expected to close o",
    "url": "https://finnhub.io/api/news?id=05e52133ae51b8a6f4b5aa2a198467137e063dbd625cace67d0d720535492432",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755139140,
      "headline": "Solventum Announces Pricing of Secondary Offering of Common Stock",
      "id": 136344952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Solventum Corporation (NYSE: SOLV) (the \"Company\" or \"Solventum\") today announced the pricing of the previously announced secondary offering (the \"Offering\") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the \"Selling Shareholder\"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any of the proceeds from the Offering. The Offering is expected to close o",
      "url": "https://finnhub.io/api/news?id=05e52133ae51b8a6f4b5aa2a198467137e063dbd625cace67d0d720535492432"
    }
  }
]